Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat Mesylate in Advanced Solid Tumors
NCT06431243Phase 2Recruiting
- Sponsor
- Zenitar
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat in solid tumor and breast cancer (4 cohorts), sponsored by Zenitar. Primary endpoints: Objective Remission Rate, Safety and Tolerability and 3 more. Started May 2024; status: recruiting.
02
Drugs
purinostat
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT06431243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431243.